Preference for O-demethylation reactions in the oxidation of 2′-, 3′-, and 4′-methoxyflavones by human cytochrome P450 enzymes

References

• Androutsopoulos V, Arroo RR, Hall JF, et al. (2008). Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism. Breast Cancer Res 10:1–12.
   Web of Science ®Google Scholar
• Androutsopoulos VP, Ruparelia K, Arroo RR, et al. (2009a). CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology 264:162–70.
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Mahale S, Arroo RR, Potter G. (2009b). Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation. Oncol Rep 21:1525–8.
   PubMed Web of Science ®Google Scholar
• Androutsopoulos V, Wilsher N, Arroo RR, Potter GA. (2009c). Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450. Cancer Lett 274:54–60.
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Papakyriakou A, Vourloumis D, et al. (2010). Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol Ther 126:9–20.
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Spyrou I, Ploumidis A, et al. (2013). Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PLOS One 8:e82487– 10.
   PubMed Web of Science ®Google Scholar
• Arct J, Pytkowska K. (2008). Flavonoids as components of biologically active cosmeceuticals. Clin Dermatol 26:347–57.
   PubMed Web of Science ®Google Scholar
• Breinholt VM, Offord EA, Brouwer C, et al. (2002). In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol 40:609–16.
   PubMed Web of Science ®Google Scholar
• Brown RE, Jarvis KL, Hyland KJ. (1989). Protein measurement using bicinchoninic acid: Elimination of interfering substances. Anal Biochem 180:136–9.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Surichan S, Ruparelia K, et al. (2011). Tangeretin and its metabolite 4’-hydroxytetramethoxyflavone attenuate EGF-stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR/p70S6K. Br J Pharmacol 162:1781–91.
   PubMed Web of Science ®Google Scholar
• Fatokun AA, Liu JO, Dawson VL, Dawson TM. (2013). Identification through high-throughput screening of 4′-methoxyflavone and 3′,4′-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos. Br J Phamacol 169:1263–78.
   PubMed Web of Science ®Google Scholar
• Fatokun AA, Dawson VL, Dawson TM. (2014). Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 171:2000–16.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2014) Analysis and Characterization of Enzymes and Nucleic Acids Relevant to Toxicology. In: Hayes AW, Kruger CL, eds. Principles and methods of toxicology, 6th edn. Boca Raton, FL: Taylor and Francis, 1905–1964.
   Google Scholar
• Han S, Choi S, Chun Y-J, et al. (2012). Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35). Biol Pharm Bull 35:394–9.
   PubMed Web of Science ®Google Scholar
• Hodek P, Trefil P, Stiborová M. (2002). Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem-Biol Interact 139:1–21.
   PubMed Web of Science ®Google Scholar
• Hostetler GL, Ralston RA, Schwartz SJ. (2017). Flavones: food sources, bioavailability, metabolism, and bioactivity. Adv Nutr 8:423–35.
   PubMed Web of Science ®Google Scholar
• Kakimoto K, Murayama N, Takenaka S, et al. (2019). Cytochrome P450 2A6 and other human P450 enzymes in the oxidation of flavone and flavanone. Xenobiotica 49:131–42.
   PubMed Web of Science ®Google Scholar
• Kale A, Gawande S, Kotwal S. (2008). Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother Res 22:567–77.
   PubMed Web of Science ®Google Scholar
• Kim H-J, Lee S, Park S-K, et al. (2005). Effects of hydroxy group numbers on the B-ring of 5,7-dihydroxyflavones on the differential inhibition of human CYP 1A and CYP1B1 enzymes. Arch Pharm Res 28:1114–21.
   PubMed Web of Science ®Google Scholar
• Kim V, Yeom S, Lee Y, et al. (2018). In vitro functional analysis of human cytochrome P450 2A13 genetic variants: P450 2A13*2, *3, *4, and *10. J Toxicol Environ Health A 81:493–501.
   PubMed Web of Science ®Google Scholar
• Koirala N, Thuan NH, Ghimire GP, et al. (2016). Methylation of flavonoids: chemical structures, bioactivities, progress and perspectives for biotechnological production. Enzyme Microb Technol 86:103–16.
   PubMed Web of Science ®Google Scholar
• Nagayoshi H, Murayama N, Kakimoto K, et al. (2019a). Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. Xenobiotica 49:791–802.
   PubMed Web of Science ®Google Scholar
• Nagayoshi H, Murayama N, Kakimoto K, et al. (2019b). Oxidation of flavone, 5-hydroxyflavone, and 5,7-dihydroxyflavone to mono-, di-, and tri-hydroxyflavones by human cytochrome P450 enzymes. Chem Res Toxicol 32:1268–80.
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–8.
   PubMed Web of Science ®Google Scholar
• Parikh A, Gillam EMJ, Guengerich FP. (1997). Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol 15:784–8.
   PubMed Web of Science ®Google Scholar
• Sandhu P, Baba T, Guengerich FP. (1993). Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys 306:443–50.
   PubMed Web of Science ®Google Scholar
• Sandhu P, Guo Z, Baba T, et al. (1994). Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Arch Biochem Biophys 309:168–77.
   PubMed Web of Science ®Google Scholar
• Sansen S, Yano JK, Reynald RL, et al. (2007). Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282:14348–55.
   PubMed Web of Science ®Google Scholar
• Shen AL, Porter TD, Wilson TE, Kasper CB. (1989). Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J Biol Chem 264:7584–9.
   PubMed Web of Science ®Google Scholar
• Shimada T, Tanaka K, Takenaka S, et al. (2009). Reverse type I binding spectra of human cytochrome P450 1B1 induced by derivatives of flavonoids, stilbenes, pyrenes, naphthalenes, phenanthrenes, and biphenyls that Inhibit catalytic activity: Structure-function relationships. Chem Res Toxicol 22:1325–33.
   PubMed Web of Science ®Google Scholar
• Shimada T, Tanaka K, Takenaka S, et al. (2010). Structure–function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol 23:1921–35.
   PubMed Web of Science ®Google Scholar
• Shimada T, Kim D, Murayama N, et al. (2013). Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition. Chem Res Toxicol 26:517–28.
   PubMed Web of Science ®Google Scholar
• Shimada T, Murayama N, Kakimoto K, et al. (2018). Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants. Xenobiotica 48:565–75.
   PubMed Web of Science ®Google Scholar
• Surichan S, Androutsopoulos VP, Sifakis S, et al. (2012). Bioactivation of the citrus flavonoid nobiletin by CYP1 enzymes in MCF7 breast adenocarcinoma cells. Food Chem Toxicol 50:3320–8.
   PubMed Web of Science ®Google Scholar
• Surichan S, Arroo RR, Ruparelia K, Tsatsakis AM, et al. (2018a). Nobiletin bioactivation in MDA-MB-468 breast cancer cells by cytochrome P450 CYP1 enzymes. Food Chem Toxicol 113:228–35.
   PubMed Web of Science ®Google Scholar
• Surichan S, Arroo RR, Tsatsakis AM, Androutsopoulos VP. (2018b). Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1-mediated metabolism to the product 4′ hydroxy tangeretin. Toxicol In Vitro 50:274–84.
   PubMed Web of Science ®Google Scholar
• Walle T. (2007). Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass?. Semin Cancer Biol 17:354–62.
   PubMed Web of Science ®Google Scholar
• Walle UK, Walle T. (2007). Bioavailable flavonoids: cytochrome P450-mediated metabolism of methoxyflavones. Drug Metab Dispos 35:1985– 9.
   PubMed Web of Science ®Google Scholar
• Walle T, Ta N, Kawamori T, et al. (2007). Cancer chemopreventive properties of orally bioavailable flavonoids – methylated versus unmethylated flavones. Biochem Pharmacol 73:1288–96.
   PubMed Web of Science ®Google Scholar
• Wen L, Jiang Y, Yang J, et al. (2017). Structure, bioactivity, and synthesis of methylated flavonoids. Ann NY Acad Sci 1398:120–9.
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang X, Coburn RA, Morris ME. (2005). Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 70:627–39.
   PubMed Web of Science ®Google Scholar